Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Blood (2023) 142 (Supplement 1): 897.

https://doi.org/10.1182/blood-2023-187859

Published: 2023

Journal Articles

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Blood (2023) 142 (Supplement 1): 475.

https://doi.org/10.1182/blood-2023-188032

Published: 2023

Journal Articles

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Blood (2023) 142 (Supplement 1): 109.

https://doi.org/10.1182/blood-2023-173855

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Blood (2022) 140 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2022-171463

Published: 2022

Journal Articles

Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)

Sameem Abedin, Skyler Taylor, Guru Subramanian Guru Murthy, Lyndsey Runaas, Laura C. Michaelis, Karen-Sue Carlson, Ehab L. Atallah

Blood (2022) 140 (Supplement 1): 11020–11021.

https://doi.org/10.1182/blood-2022-160416

Published: 2022

Journal Articles

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Sameem Abedin, Guru Subramanian Guru Murthy, Aniko Szabo, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Katelyn Gauger, Avinash G Desai, Mary M Chen, Alexandra M. Harrington, Ehab L. Atallah

Blood (2022) 140 (Supplement 1): 157–158.

https://doi.org/10.1182/blood-2022-157827

Published: 2022

Journal Articles

Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Blood (2022) 140 (Supplement 1): 5083–5085.

https://doi.org/10.1182/blood-2022-159809

Published: 2022

Journal Articles

Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems

Ravi Kishore Narra, Ehab L. Atallah, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Aniko Szabo, Guru Subramanian Guru Murthy

Blood (2022) 140 (Supplement 1): 6035–6036.

https://doi.org/10.1182/blood-2022-165392

Published: 2022

Journal Articles

A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)

Guru Subramanian Guru Murthy, Scott H. Kaufmann, Aniko Szabo, Alexandra M. Harrington, Laura C. Michaelis, Sameem Abedin, Karen Carlson, Lyndsey Runaas, Walter L. Longo, Alexander Hinman, Sonia Maldonado-Schmidt, Althea Thomas, Arielle Baim, Mark R. Litzow, Ehab L. Atallah

Blood (2021) 138 (Supplement 1): 2347.

https://doi.org/10.1182/blood-2021-149351

Published: 2021

Journal Articles

Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study

Sameem Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, Laura C. Michaelis, Lyndsey Runaas, Karen Carlson, Ehab L. Atallah

Blood (2021) 138 (Supplement 1): 3414.

https://doi.org/10.1182/blood-2021-148746

Published: 2021

Journal Articles

MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Blood (2021) 138 (Supplement 1): 2955.

https://doi.org/10.1182/blood-2021-149313

Published: 2021

Journal Articles

A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma

Blood (2021) 138 (Supplement 1): 4401.

https://doi.org/10.1182/blood-2021-149329

Published: 2021

Journal Articles

A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML

Sameem Abedin, MD, Guru Subramanian Guru Guru Murthy, MBBS, Mehdi Hamadani, MD, Laura C. Michaelis, MD, Lyndsey Runaas, MD, Karen-Sue Carlson, MDPhD, Alexandra M. Harrington, MDMT(ASCP), Ehab L. Atallah, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137218

Published: 2020

Journal Articles

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

Kristen M Corrao, MD, Alexandra M. Harrington, MDMT(ASCP), Steven H. Kroft, MD, Laura C. Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Lyndsey Runaas, MD, Ehab L. Atallah, MD, Sameem Abedin, MD

Blood (2019) 134 (Supplement_1): 5430.

https://doi.org/10.1182/blood-2019-130511

Published: 2019

Journal Articles

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Talha Badar, MD, Guru Subramanian Guru Murthy, MD, Lyndsey Runaas, MD, Karen-Sue B. Carlson, MD PhD, Laura C. Michaelis, MD, Alexandra M. Harrington, MDMT(ASCP), Ehab L. Atallah, MD, Sameem Abedin, MD

Blood (2019) 134 (Supplement_1): 5068.

https://doi.org/10.1182/blood-2019-123237

Published: 2019

Journal Articles

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Guru Subramanian Guru Guru Murthy, MBBS, Scott H. Kaufmann, MD PhD, Aniko Szabo, PhD, Arielle Baim, Ashish Anshu, Alexander Hinman, Laura C. Michaelis, MD, Sameem Abedin, MD, Karen-Sue B. Carlson, MD PhD, Lyndsey Runaas, MD, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 3837.

https://doi.org/10.1182/blood-2019-131728

Published: 2019

Journal Articles

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

Sameem Abedin, MD, Guru Subramanian Guru Murthy, MBBS, Lyndsey Runaas, MD, Laura C. Michaelis, MD, Ehab L. Atallah, MD, Mehdi Hamadani, MD, Alexandra M. Harrington, MDMT(ASCP), Karen Carlson, MD

Blood (2019) 134 (Supplement_1): 2605.

https://doi.org/10.1182/blood-2019-122487

Published: 2019

Journal Articles

Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens

Alexandra Rezazadeh, MD, Gemlyn George, MD, Nicole Pearl, PharmD, Cole McCoy, Felicia Zook, Benjamin Jung, Aschenbrenner Emilie, Mindy Waggoner, Sameem Abedin, MD, Lyndsey Runaas, MD, Laura C. Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Lisa Baumann Kreuziger, MD MS, Ehab L. Atallah, MD

Blood (2018) 132 (Supplement 1): 1232.

https://doi.org/10.1182/blood-2018-99-114597

Published: 2018

Journal Articles

40 Is the New 50: Reducing the Need for Platelet Transfusions Prior to Lumbar Puncture in Patients with Hematologic Malignancies

Kristen M Corrao, MD, Laura C. Michaelis, MD, Lisa Baumann Kreuziger, MD MS, Karen-Sue B. Carlson, MD PhD, Sameem Abedin, MD, Elizabeth Malosh, MSN, RN, David Atkinson, Wenjing Shan, Stephen Quinet, MD MPH, Adrian P Umpierrez De Reguero, MD, DeLisle Julie, RN, MSN, Angela Treml, MD, Lyndsey Runaas, MD, Ehab L. Atallah, MD

Blood (2018) 132 (Supplement 1): 4837.

https://doi.org/10.1182/blood-2018-99-114264

Published: 2018

Journal Articles

Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results

Ensi Voshtina, DO, Arun K Singavi, MD, Amanda Jacquart, MS, CGC, Lyndsey Runaas, MD, Ehab L. Atallah, MD, Laura C. Michaelis, MD, Sameem Abedin, MD

Blood (2018) 132 (Supplement 1): 2253.

https://doi.org/10.1182/blood-2018-99-117020

Published: 2018

NARROW

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems

A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)

Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study

MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma

A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens

40 Is the New 50: Reducing the Need for Platelet Transfusions Prior to Lumbar Puncture in Patients with Hematologic Malignancies

Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only